[Level of adalimumab and its antibody titers define the effectiveness of the biological (anticytokine) therapy in Crohn's disease].
Formation of immune antibodies to adalimumab (ADM) in patients with Crohn's disease currently has high clinical value, as antibodies (AT) influence on bioavailability, pharmacokinetic, pharmacodynamic indicators, that eventually affects expression of clinical response to treatment. The results of this study indicate that after treatment with adalimumab in 12-14 weeks in any case there was not an increase of antibodies to adalimumab. Synchronous study of concentration of adalimumab (ADA) and antibodies to ADA in serum to determine the effectiveness of anti-cytokine therapy with adalimumab in Crohn's disease.
L B
LB
Lazebnik
V É
VÉ
Sagynbaeva
D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000097:blood*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003424:Crohn Disease / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000097:blood / Q000276:immunology; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab